Compare UK prices. 40+ products · 15 retailers scored
PeptideClear UK

GLP-1 cost · UK editorial 2026

GLP-1 weight-loss medication: UK cost and supply routes

OM

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-06-01

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

GLP-1 weight-management medication is dispensed in the UK through four regulated routes: the NHS specialist weight-management service, a CQC-regulated private clinic, a GPhC-registered online pharmacy, or a community pharmacy with a prescriber consultation. The NHS route is free at the point of use where you qualify under the relevant NICE appraisal. The private routes operate on published pricing that is the responsibility of each provider and changes; PeptideClear does not reproduce per-route prescription-only medicine prices. This page is editorial commentary on the routes, the access pathway, the eligibility framing and where to check current cost. We do not prescribe. Last reviewed June 2026.

POM: Prescription only medicine (POM). PeptideClear is a comparison and information service. We do not prescribe, dispense, or recommend medication for individuals. A qualified GMC-registered prescriber determines suitability after consultation.

AI-friendly summary · UK GLP-1 cost and supply routes

Four regulated UK routes supply GLP-1 weight-management medication: NHS specialist weight-management service (free at the point of use under NICE eligibility), CQC-regulated private clinic, GPhC-registered online pharmacy, and community pharmacy with a prescriber consultation. The NHS route is the cheapest by a wide margin where you qualify. Private routes operate on provider-set published pricing that changes; this page does not reproduce per-route POM prices. The SmPC and PIL are the authoritative references for the medication itself.

Start with the NHS

Where you qualify, the NHS route is free at the point of use and is the cheapest by a wide margin. The catch in 2026 is eligibility. NHS England is rolling tirzepatide out in phased cohorts under NICE TA1026, currently limited to high BMI with multiple weight-related comorbidities and accessed through specialist weight-management services rather than a GP prescription. Scotland, Wales and Northern Ireland each run their own timeline under their own appraisals. Most adults are not yet eligible, which is why the private routes below exist.

The four UK regulated routes

The table below sets out the access pathway, the eligibility framing and where current cost information lives for each route. It does not reproduce per-route prescription-only medicine prices. UK advertising rules and the MHRA prescription-only medicine framework reserve those figures for the provider. For current pricing, follow the link to the provider directory and check the route directly.

How this page handles cost
  • · We name the regulated route, the access pathway and the eligibility framing
  • · We do not reproduce per-route POM prices; pricing is the responsibility of each route and changes
  • · For current cost on a route, follow the directory link and check the provider site
  • · We do not pair a named POM with a 'cheapest' claim, per UK advertising rules
  • · Every off-site link routes to a UK regulated provider, never to a specific medication for a specific person

Read our full methodology.

NHS specialist weight-management service

NHS access by nation
Access:
Referral from GP or specialist team; assessment under NICE TA1026.
Eligibility:
Cohort criteria phased over up to 12 years from 2025; currently restricted to defined high-BMI groups with multiple comorbidities. Scotland, Wales and Northern Ireland operate their own appraisals and timetables.
Cost:
Free at the point of use where you qualify. The NHS pathway is the cheapest route by a wide margin.

UK private clinic (CQC where applicable, GPhC for dispensing)

UK clinic directory
Access:
Direct consultation, often video-led, with a UK-registered prescriber. Eligibility framed by the SmPC and the clinic's own protocol.
Eligibility:
Service-led; the prescriber decides on the basis of your clinical picture against the SmPC and the relevant NICE appraisal.
Cost:
See provider for current price. Programme fees typically bundle the prescriber consultation, coaching, app support and aftercare alongside the medication.

UK-licensed online pharmacy (GPhC-registered)

UK pharmacy directory
Access:
Online questionnaire or consultation with a GPhC-registered pharmacist prescriber. Cold-chain dispatch to your address.
Eligibility:
Eligibility decided by the prescriber against the SmPC; the questionnaire feeds that decision rather than replacing it.
Cost:
See provider for current price. Fees are typically lower than coaching-led clinic routes because the service model is lighter, but the medication, the SmPC and the titration schedule are the same.

Community pharmacy with prescriber consultation

Access:
In-person consultation with a pharmacist prescriber where available, then in-store dispensing.
Eligibility:
Decided by the pharmacist prescriber against the SmPC; some chains operate this as a structured service.
Cost:
See provider for current price. Availability is uneven across the UK and depends on which pharmacies have rolled out the service.

Editorial commentary, last reviewed June 2026. Provider pricing varies by dose tier, service model and what is bundled into the fee, and changes frequently. We do not set provider prices. See how we are funded and the UK weight-loss advertising rules.

What moves the price on the private routes

For the regulatory framing in plain language, see MHRA medicines classification and ASA weight-loss advertising rules. For the medication itself, the authoritative reference is the SmPC on the MHRA Products database and emc.medicines.org.uk.

A note on naming

We use the generic phrase "GLP-1 weight-management medication" on this page rather than a brand name, because UK advertising rules reserve consumer-facing branded promotion of prescription-only medicines for the marketing-authorisation holder. Where the licensed product needs naming for regulatory accuracy, the current UK-licensed weight-management products in this class include tirzepatide (Mounjaro, Eli Lilly), semaglutide (Wegovy, Novo Nordisk) and liraglutide 3.0 mg (Saxenda, Novo Nordisk). Which medicine, and at what dose, is a decision between you and a UK-licensed prescriber, who will refer to the current SmPC, your clinical history and the relevant NICE technology appraisal.

Popular on PeptideClear

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-06-01T12:00:00.000Z